Correvio Pharma Corp., of Vancouver, British Columbia, said it completed its at-the-market offering of 4.3 million common shares at an average price of $2.71 each, resulting in net proceeds of approximately $11.5 million. The proceeds provide it with sufficient capital to operate its business through the submission and FDA review of the new drug application filing for heart drug Brinavess (vernakalant hydrochloride).